Basic notitia
| Product Name | Catalogue | Type | Host/Source | Consuetudinem | Applications | Epitope | COA |
| HCV Core-NS3-NS5 fusionem antigen | BMIHCV203 | Antigen | E.coli | Excipio | CMIA,WB | / | Download |
| HCV Core-NS3-NS5 fusionem antigen | BMIHCV204 | Antigen | E.coli | Conjugate | CMIA,WB | / | Download |
| HCV Core-NS3-NS5 fusionem antigen-Bio | BMIHCVB02 | Antigen | E.coli | Conjugate | CMIA,WB | / | Download |
| HCV Core-NS3-NS5 fusionem antigen | BMIHCV213 | Antigen | HEK293 Cell | Conjugate | CMIA,WB | / | Download |
pathogenesis hepatitis C adhuc obscura est.Cum HCV in cellulis iecoris replicat, mutationes in structura et functione cellularum hepatis creat vel impedit synthesim iecoris cellae, quae degenerationem et necrosim cellularum iecoris causare potest, significans HCV directe laedere iecur et partes agere in pathogenesi.Multi tamen mathematici putant reactionem immunopathologicam cellularem momenti magni momenti habere posse.Hepatitis C, sicut hepatitis B, invenerunt habere cellulas CD3+ maxime in filtrando.Cytotoxicae T cellulae (TC) specialiter oppugnant cellulas infectio HCV quae damnum cellae hepatis causare potest.
RIA vel ELISA
Radioimmunodiagnosis (RIA) vel enzyme-coniunctum immunosorbenti primordium (ELISA) adhibitum est ad deprehendendum anti HCV in Serum.In 1989, Kuo et al.methodum radioimmunoassay (RIA) pro anti-C-100 instituit.Postea, Ortho Societas feliciter enzyme connexa immunosorbenti (ELISA) ad detectionem anti-C-100 evolvit.Utriusque modi fermentum recombinantis uti antigenis virus expressit (C-100-3, interdum a NS4 encoded, amino acida continens 363), post purificationem parvis foraminibus plasticae moles obducta est, et postea cum sero probata additur.Virus antigenum tunc coniungitur cum anti-C-100 in sero probato.Denique isotope vel enzyme intitulatum mus anti humano lgG monoclonali anticorpori additur, et subiectum colori determinationi additur.
